- Home
- PEN
PEN
Penumbra Inc.
as 04-18-2025 1:41pm EST
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
Upcoming Earnings Alert:
Get ready for potential market movements as Penumbra Inc. PEN prepares to release earnings report on 23 Apr 2025.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 10.5B | IPO Year: | 2015 |
| Target Price: | $290.93 | AVG Volume (30 days): | 451.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.36 | EPS Growth: | -84.48 |
| 52 Week Low/High: | $148.00 - $310.00 | Next Earning Date: | 04-23-2025 |
| Revenue: | $1,194,615,000 | Revenue Growth: | 12.86% |
| Revenue Growth (this year): | 14.26% | Revenue Growth (next year): | 14.21% |
Stock Insider Trading Activity of Penumbra Inc. (PEN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| O'Rourke Bridget | PEN | Director | Apr 15 '25 | Sell | $271.21 | 50 | $13,560.50 | 5,523 | |
| Wilder Thomas | PEN | Director | Apr 2 '25 | Sell | $266.93 | 360 | $96,094.80 | 4,692 | |
| Elsesser Adam | PEN | CEO and President | Apr 2 '25 | Sell | $272.32 | 16,565 | $4,509,728.21 | 58,244 | |
| Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Apr 1 '25 | Sell | $267.89 | 600 | $161,466.15 | 66,826 | |
| Grewal Harpreet | PEN | Director | Apr 1 '25 | Sell | $267.17 | 200 | $53,434.00 | 9,074 | |
| Wilder Thomas | PEN | Director | Mar 31 '25 | Sell | $264.58 | 360 | $95,248.80 | 4,692 | |
| Bose Arani | PEN | Director | Mar 25 '25 | Sell | $284.79 | 12,000 | $3,405,252.50 | 324,931 | |
| Elsesser Adam | PEN | CEO and President | Mar 19 '25 | Sell | $275.03 | 16,600 | $4,585,137.64 | 58,244 | |
| Elsesser Adam | PEN | CEO and President | Mar 5 '25 | Sell | $283.72 | 61,600 | $17,468,917.42 | 58,244 | |
| Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Mar 3 '25 | Sell | $287.25 | 600 | $172,458.48 | 66,826 |
Latest Penumbra Inc. News
PEN Breaking Stock News: Dive into PEN Ticker-Specific Updates for Smart Investing
StockStory
2 days ago
Reflecting On Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks’ Q4 Earnings: Merit Medical Systems (NASDAQ:MMSI)
Zacks
3 days ago
Penumbra (PEN) Earnings Expected to Grow: Should You Buy?
Argus Research
3 days ago
PEN: Raising target price to $286.00
StockStory
4 days ago
Unpacking Q4 Earnings: Artivion (NYSE:AORT) In The Context Of Other Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks
StockStory
10 days ago
3 Reasons PEN is Risky and 1 Stock to Buy Instead
Argus Research
10 days ago
PEN: Lowering target price to $269.00
Zacks
11 days ago
Reasons to Retain Penumbra Stock in Your Portfolio for Now
PR Newswire
15 days ago
Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025
Compare PEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PEN Penumbra Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.